Keywords: nitromed, bidil, achieves, ph, iii, goals, firm

NitroMed's BiDil achieves Ph III goals

Article | 26 July 2004

Print This

US firm NitroMed has halted a Phase III trial of BiDil (isosorbidedinitrate and hydralazine), its lead drug in development for ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in